Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies
Top Cited Papers
- 1 July 2016
- journal article
- research article
- Published by Elsevier BV in The Lancet Respiratory Medicine
- Vol. 4 (7), 549-556
- https://doi.org/10.1016/s2213-2600(16)30031-5
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Severe adult-onset asthma: A distinct phenotypeJournal of Allergy and Clinical Immunology, 2013
- Targeting eosinophils in allergy, inflammation and beyondNature Reviews Drug Discovery, 2013
- Severe asthma: from characteristics to phenotypes to endotypesClinical and Experimental Allergy, 2012
- Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard TherapyAnnals of Internal Medicine, 2011
- An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and ExacerbationsAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Heterogeneity of asthma according to blood inflammatory patternsThorax, 2009
- Severe Exacerbations and Decline in Lung Function in AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2009
- The cost of dichotomising continuous variablesBMJ, 2006
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004
- Proceedings of the ATS Workshop on Refractory AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2000